An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

Launched by SHANGHAI GENERAL HOSPITAL, SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · Aug 29, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called AAV2-RPE65 gene therapy (LX101) for patients with a rare eye condition known as congenital amaurosis (LCA), which can cause severe vision loss or blindness from a young age. The main goal of the study is to see how effective this gene therapy is in improving vision for those affected by LCA.

To participate, individuals must have previously taken part in an earlier study of the same treatment and be willing to commit to long-term follow-up. However, certain eye conditions or other health issues may prevent someone from joining the trial. For example, individuals with serious eye problems or specific systemic diseases that could impact eye health will not be eligible. Participants can expect to receive close medical attention and monitoring throughout the study to ensure their safety and to assess how well the treatment works. It's important for potential participants to discuss their health history with their doctor to see if they qualify for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1) Participants in the main study "Exploratory clinical study evaluating AAV2-RPE65 gene therapy formulation (LX101) in patients with congenital amaurosis (LCA) 2) Willingness to participate in the extended study, subject and/or their guardian signing a written informed consent and complying with a long-term follow-up protocol
• Exclusion Criteria:
• * Have any of the following eye conditions:
• • 1. Subjects with SAE in the "Exploratory clinical Study Evaluating AAV2-RPE65 gene therapy agent (LX101) in patients with congenital Amaurosis (LCA)
• • 2. pre-existing eye conditions (such as glaucoma, cornea, or severe lens opacity) that the investigator determines may interfere with planned surgery or with interpretation of the study endpoint;
• • 3. Screening subjects who had undergone any internal eye surgery in the six months prior to the visit;
• • 4. Inability or unwillingness to meet the requirements of the study;
• Have any of the following systemic conditions:
• • 6) Known allergy to the drug planned for use in the study; 7) Have a history of surgical operations within 1 month before enrollment, and/or present unhealed wounds, ulcers, fractures, etc.; Present infectious disease requiring oral, intramuscular or intravenous administration; 8) Baseline laboratory values for complex systemic diseases or clinically significant abnormalities; 9) Complex systemic diseases include diseases in which the disease itself or the treatment of the disease can alter eye function. For example, the treatment of malignant tumors can affect central nervous system function (e.g., orbital radiation therapy; Leukemia with central/optic nerve involvement); 10) Subjects with a history of immune-damaging diseases due to the possibility of opportunistic infection (e.g., CMV retinitis); Subjects with diabetes or sickle cell disease will be excluded if they have any manifestations of advanced retinopathy, such as macular edema or proliferative changes. Subjects with juvenile rheumatoid arthritis have an increased risk of infection due to poor postoperative wound healing; 11) Participants who cannot discontinue Viagra (Sildenafil) or related compounds used to treat erectile dysfunction during the study period; 12) Subjects who cannot discontinue hydroxychloroquine, Chloroquine, meralide, or any related retinal toxic compound during the study; 13) Any other conditions in which the potential subject is not allowed to complete a follow-up examination during the study, and the investigator believes that there are conditions that make the potential subject unfit for the study.
• Fertile subjects with any of the following conditions:
• • 14) Those who do not use effective contraceptive measures; 15) Pregnant and lactating women.